ACMD meeting statement, Meeting 33, 1 June 2017

Role of the ACMD in the TGA’s regulatory decision making process

The Advisory Committee on Medical Devices (ACMD) is a statutory advisory committee established by the Therapeutic Goods Regulations 1990. The committee provides independent expert advice on specific scientific and technical matters in order to aid the TGA’s decision making and other regulatory processes.

While the advice provided by the ACMD is an important element in the undertaking of the TGA’s regulatory functions it forms only part of the information that is available to delegates when they make a regulatory decision under the Therapeutic Goods Act 1989. It is important to note that while appropriate consideration will always be given to such advice, the TGA is not obliged to follow the specific recommendations and advice given by the committee.

It should also be noted that information about advice provided by the committee may not become publicly available for some time after the committee has provided that advice. The purpose of this Meeting Statement is to describe in general terms the matters considered by the committee at each meeting and for it to be available as soon as reasonably practical after the relevant meeting.

Update on matters where the Committee previously provided advice and a TGA decision has been made

The committee was advised that the application for the left ventricular assist system considered at the 32nd meeting is nearly finalised.

The committee received an update advising that the neurovascular embolization system considered at the 32nd meeting has been withdrawn by the applicant.

The committee was advised that the application for the aortic annuloplasty ring considered at the 32nd meeting will be finalised shortly.

Overview of the therapeutic goods referred for advice

At the 33rd ACMD meeting the committee considered the following devices:

• Two complete implantable knee systems;
• A cruciate retaining, tibial component from an implantable knee system;
• Multiple femoral stems from different implantable hip systems;
• Multiple implantable acetabular cups and inserts;

The committee considered whether the benefits outweighed the risks for the devices and whether adequate evidence has been provided to demonstrate safety and performance through compliance with the Essential Principles.

Overview of the post market issues referred for advice

At the 33rd ACMD meeting the committee considered the following post market item:

• Bone substitutes and fillers.

The committee’s advice has now been provided to the TGA for consideration as part of the TGA’s regulatory decision-making processes.

Further information

Meeting statements are made publicly available after each meeting.

For further information on the ACMD, please visit the ACMD web page or contact the ACMD Secretary by phone on (02) 6232 8734 or email: acmd@health.com.au